Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Patrick Forde

Patrick Prendergast Professor of Immuno- (Surgery)
      
Profile Photo

Professor Patrick Forde

Patrick Prendergast Professor of Immuno- (Surgery)

 fordep1@tcd.ie

 


Prof. Patrick Forde is Prendergast Professor of Immuno-Oncology at Trinity College Dublin and Consultant Medical Oncologist at St. James Hospital Dublin as well as a professor at Johns Hopkins University. He has led the development of immunotherapy for surgically resectable lung cancer from initial concept to worldwide use, initially exploring the role of single agent anti-PD-1 as neoadjuvant therapy and later as principal investigator of the CheckMate 816 trial which led to the approval internationally of neoadjuvant chemo-immunotherapy for stage II-III lung cancer. Long term follow up from this study showed that just 3 doses of immunotherapy before surgery significantly improved long term survival for patients with lung cancer. He leads several translational efforts to optimize the treatment of lung cancer including the global platform neoadjuvant immunotherapy trial, NeoCOAST-2, exploring novel immunotherapy combinations prior to surgery for lung cancer.
Details Date From Date To
Member of European Society of Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N;, Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer, New England Journal of Medicine, 2025, Journal Article, PUBLISHED  DOI
Cappelli, L.C., Bingham, C.O., Forde, P.M., Anagnostou, V., Brahmer, J., Lipson, E.J., Mammen, J., Schollenberger, M., Shah, A.A., Darrah, E., Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis, RMD Open, 8, (2), 2022, Journal Article, PUBLISHED  DOI
Ricciuti, B., Wang, X., Alessi, J.V., Rizvi, H., Mahadevan, N.R., Li, Y.Y., Polio, A., Lindsay, J., Umeton, R., Sinha, R., Vokes, N.I., Recondo, G., Lamberti, G., Lawrence, M., Vaz, V.R., Leonardi, G.C., Plodkowski, A.J., Gupta, H., Cherniack, A.D., Tolstorukov, M.Y., Sharma, B., Felt, K.D., Gainor, J.F., Ravi, A., Getz, G., Schalper, K.A., Henick, B., Forde, P., Anagnostou, V., Jänne, P.A., Van Allen, E.M., Nishino, M., Sholl, L.M., Christiani, D.C., Lin, X., Rodig, S.J., Hellmann, M.D., Awad, M.M., Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers with Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels, JAMA Oncology, 8, (8), 2022, p1160-1168 , Journal Article, PUBLISHED  DOI
Rosner, S., Liu, C., Forde, P.M., Hu, C., Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis, JTO Clinical and Research Reports, 3, (9), 2022, Journal Article, PUBLISHED  DOI
Rosner, S., Forde, P.M., Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC, Journal of Thoracic Oncology, 17, (4), 2022, p503-509 , Journal Article, PUBLISHED  DOI
Liang, W., Cai, K., Cao, Q., Chen, C., Chen, H., Chen, J., Chen, K.-N., Chen, Q., Chu, T., Dong, Y., Fan, J., Fang, W., Fu, J., Fu, X., Gao, S., Ge, D., Geng, G., Geng, Q., He, J., Hu, J., Hu, J., Hu, W.-D., Jiang, F., Jiang, T., Jiao, W., Li, H.-C., Li, Q., Li, S., Li, S., Li, X., Liao, Y.-D., Liu, C., Liu, H., Liu, Y., Lu, Z., Luo, Q., Ma, H., Pan, X., Qiao, G., Ren, S., Shen, W., Song, Y., Sun, D., Wang, G., Wang, J., Wang, M., Wang, Q., Wang, W.-X., Wei, L., Wu, M., Wu, N., Xia, H., Xu, S.-D., Yang, F., Yang, K., Yang, Y., Yu, F., Yu, Z.-T., Yue, D.-S., Zhang, L., Zhang, W., Zhang, Z., Zhao, G., Zhao, J., Zhao, X., Zhou, C., Zhou, Q., Zhu, K., Zhu, Y., Hida, T., Dempke, W.C.M., Rossi, A., de Perrot, M., Ramirez, R.A., Provencio, M., Lee, J.M., Passaro, A., Spaggiari, L., Spicer, J., Girard, N., Forde, P.M., Mok, T.S.K., Cascone, T., He, J., International expert consensus on immunotherapy for early-stage non-small cell lung cancer, Translational Lung Cancer Research, 11, (9), 2022, p1742-1762 , Journal Article, PUBLISHED  DOI
Hsu, M.L., Murray, J.C., Psoter, K.J., Zhang, J., Barasa, D., Brahmer, J.R., Ettinger, D.S., Forde, P.M., Hann, C.L., Lam, V.K., Levy, B., Marrone, K.A., Patel, T., Peterson, V., Sagorsky, S., Turner, M., Anagnostou, V., Naidoo, J., Feliciano, J.L., Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy, Oncologist, 27, (11), 2022, p971-981 , Journal Article, PUBLISHED  DOI
Friedlaender, A., Naidoo, J., Luigi Banna, G., Metro, G., Forde, P., Addeo, A., Corrigendum to "Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC" [Cancer Treat. Rev. 104 (2022) 102350] (Cancer Treatment Reviews (2022) 104, (S0305737222000135), (10.1016/j.ctrv.2022.102350)), Cancer Treatment Reviews, 104, 2022, Journal Article, PUBLISHED  DOI
Guo, M.Z., Murray, J.C., Ghanem, P., Voong, K.R., Hales, R.K., Ettinger, D., Lam, V.K., Hann, C.L., Forde, P.M., Brahmer, J.R., Levy, B.P., Feliciano, J.L., Marrone, K.A., Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer, Clinical Lung Cancer, 23, (7), 2022, p620-629 , Journal Article, PUBLISHED  DOI
Gridelli, C., Peters, S., Mok, T., Forde, P.M., Reck, M., Attili, I., de Marinis, F., First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology, ESMO Open, 7, (1), 2022, Journal Article, PUBLISHED  DOI
  

Page 1 of 7

  


Award Date
ECOG-ACRIN Young Investigator Award 2023
Daniel C. Ihde Award for Medical Oncology, International Association for the Study of Lung Cancer 2022